Shares of Tiziana Life Sciences PLC (NASDAQ:TLSA) rose 3.5% during trading on Monday . The stock traded as high as $6.15 and last traded at $6.15, approximately 30 shares changed hands during mid-day trading. A decline of 100% from the average daily volume of 15,598 shares. The stock had previously closed at $5.94.
Separately, Laidlaw set a $20.00 target price on shares of Tiziana Life Sciences and gave the company a “buy” rating in a research report on Tuesday, September 10th.
The business’s 50-day simple moving average is $6.09 and its 200 day simple moving average is $7.08.
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
See Also: Bull Market
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.